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Because aortic root dilatation and resulting dissection 
are the most life-threatening problems in patients 
with Marfan syndrome, research has focused on 
mitigating the risk for these complications. Whereas 
surgical replacement of the dilated aorta remains the 
most effective intervention, medical treatment aimed 
at reducing aortic root growth also contributes to 
improved outcome. β blockers are considered the gold 
standard for this purpose, with an effect most likely 
achieved by reducing aortic wall shear stress.1
A major discovery in the research to unravel the 
underlying pathogenesis of this condition was 
the demonstration of the transforming growth 
factor β (TGF-β) pathway involvement.2 This opened-
up perspectives for new treatment options through 
blockade of TGF-β, where angiotensin-II receptor 
blockers (ARBs) seemed an attractive option. The 
precise contribution of TGF-β has still not been fully 
elucidated. It has been shown that TGF-β has dual 
effects and should be regarded as a marker rather than 
a cause of pathology.3 Nevertheless, the publication of 
the remarkable results, showing that losartan, an ARB, 
improved aortic growth in a mouse model of Marfan 
syndrome, had an impact in the Marfan syndrome 
community.4 At least eight studies with losartan have 
been done.5–8 Albeit with variable study design and 
populations, these studies showed that the results 
achieved in animal models could not be replicated in 
humans, leading to further speculation about possible 
explanations.
One of the hypotheses was that the lower 
bioavailability (33%) and short half-life (2 h)9 of losartan 
might provide insufficient protection. Therefore, 
irbesartan, an ARB with longer bioavailability (up 
to 80%) and half-life (up to 15 h),9 could result in 
a better outcome. For this reason, the study by 
Michael Mullen and colleagues10 in The Lancet is very 
interesting. This randomised placebo-controlled trial 
shows that the intake of irbesartan significantly reduced 
aortic root dilatation in patients with Marfan syndrome 
(mean aortic root growth 0·53 mm per year [95% CI 
0·39 to 0·67] in the irbesartan group vs 0·74 mm per 
year [0·60 to 0·89] in the placebo group; difference 
–0·22 mm per year [–0·41 to –0·02]; p=0·030). This 
moderate effect was mainly achieved during the first 
year of treatment and was maintained throughout 
the 4 subsequent years. A parallel effect was observed 
on blood pressure, suggesting a possible association 
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essential component in the chain of survival. We believe 
that this study12 should further stimulate efforts by 
those in positions of influence to facilitate widespread 
access to public-access defibrillation in the general 
community.
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between lowering blood pressure and aortic growth. 
On the basis of these findings, previous conclusions 
are confirmed: the use of ARBs to inhibit aortic growth 
in patients with Marfan syndrome can certainly be 
considered.
Several recurring and unresolved questions in the 
design and interpretation of studies of ARBs have 
unfortunately not been clarified by this study either. 
First, many such studies are confronted with the 
issue of difficult patient recruitment. In the study 
by Mullen and colleagues,10 not even half of the 
anticipated number of patients was achieved. This 
difficulty has to do with the rarity of the condition 
and with the difficulty of convincing patients to 
participate in research after the publication of 
preclinical trials.
Second, another limiting factor is the low hard event 
rate (aortic dissection and death), which forces all 
studies to rely on indirect outcome parameters, such 
as aortic root growth. Furthermore, an additional 
limitation of this study is the inclusion of both children 
and adults (192 patients with Marfan syndrome with 
a median age of 18 years [IQR 12–28]). Apart from 
somatic growth in half of the study population, which 
is difficult to account for, there is the problem of the 
measurement of the aorta itself and the calculation 
of the Z scores. Although aortic Z score values were 
used as a secondary outcome in this study, applying 
methods for Z score calculation based on data 
obtained in different age populations and using 
different echocardiographic methods is cumbersome. 
The authors sought to solve this difficulty by 
calculating the Z score according to the Devereux 
method11 (developed for application in adult patients) 
while using the Pettersen reference12 (developed for 
application in paediatric patients) as a sensitivity 
analysis.
A final consideration is that 108 (56%) patients in 
the cohort were taking β blockers. The authors tried 
to account for the confounding effect of β blockers 
through conventional stratified analysis, but the study 
was underpowered to perform meaningful subgroup 
evaluation (especially given the drop-out rate of 24% 
in the irbesartan group and 15% in the placebo group). 
Subsequently, evaluation of how the observed effect 
should be interpreted is difficult. Is the effect of the 
irbesartan better in comparison to no treatment or in 
comparison to β blocker treatment? What is the effect 
of combined treatment?
Despite these limitations, the study by Mullen and 
colleagues10 is valuable and certainly adds to the 
ongoing discussion on how to best treat patients with 
Marfan syndrome. A planned meta-analysis of trials 
done thus far13 will hopefully provide some answers 
that are urgently needed for this community.
*Laura Muiño-Mosquera, Julie De Backer
Department of Paediatrics, Division of Paediatric Cardiology 
(LM-M), Centre for Medical Genetics (LM-M, JDB), and Department 
of Cardiology (JDB), Ghent University Hospital, Ghent 9000, 
Belgium 
laura.muinomosquera@uzgent.be
We declare no competing interests.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open 
Access article under the CC BY-NC-ND 4.0 license.
1 Shores J, Berger K, Murphy EA, Pyeritz RE. Progression of aortic dilatation 
and the benefit of long-term β-adrenergic blockade in Marfan’s syndrome. 
N Engl J Med 330: 1335–41.
2 Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-β 
activation contributes to pathogenesis in Marfan syndrome. Nat Genet 
2003; 33: 407–11.
3 Cook JR, Clayton NP, Carta L, et al. Dimorphic effects of transforming 
growth factor-β signaling during aortic aneurysm progression in mice 
suggest a combinatorial therapy for Marfan syndrome. 
Arterioscler Thromb Vasc Biol 2015; 35: 911–17.
4 Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents 
aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 
312: 117–21.
5 Chiu H-H, Wu M-H, Wang J-K, et al. Losartan added to β-blockade therapy 
for aortic root dilation in Marfan syndrome: a randomized, open-label pilot 
study. Mayo Clin Proc 2013; 88: 271–76.
6 Muiño-Mosquera L, De Nobele S, Devos D, Campens L, De Paepe A, 
De Backer J. Efficacy of losartan as add-on therapy to prevent aortic growth 
and ventricular dysfunction in patients with Marfan syndrome: 
a randomized, double-blind clinical trial. Acta Cardiol 2017; 72: 616–24.
7 Teixido-Tura G, Forteza A, Rodríguez-Palomares J, et al. Losartan versus 
atenolol for prevention of aortic dilation in patients with Marfan 
syndrome. J Am Coll Cardiol 2018; 72: 1613–18.
8 Li L, Yamani N, Al-Naimat S, Khurshid A, Usman MS. Role of losartan in 
prevention of aortic dilatation in Marfan syndrome: a systematic review 
and meta-analysis. Eur J Prev Cardiol 2019; published online July 1. 
DOI:10.1177/2047487319861231.
9 Abraham HMA, White CM, White WB. The comparative efficacy and 
safety of the angiotensin receptor blockers in the management of 
hypertension and other cardiovascular diseases. Drug Saf 2015; 
38: 33–54.
10 Mullen M, Jin XY, Child A, et al. Irbesartan in Marfan syndrome (AIMS): 
a double-blind, placebo-controlled randomised trial. Lancet 2019; published 
online Dec 10. https://doi.org/10.1016/S0140-6736(19)32518-8. 
11 Devereux RB, de Simone G, Arnett DK, et al. Normal limits in relation to 
age, body size and gender of two-dimensional echocardiographic aortic 
root dimensions in persons ≥15 years of age. Am J Cardiol 2012; 
110: 1189–94.
12 Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for 
calculation of Z scores of cardiac structures in a large cohort of healthy 
infants, children, and adolescents: an echocardiographic study. 
J Am Soc Echocardiogr 2008; 21: 922–34.
13 Pitcher A, Emberson J, Lacro RV, et al. Design and rationale of a prospective, 
collaborative meta-analysis of all randomized controlled trials of 
angiotensin receptor antagonists in Marfan syndrome, based on individual 
patient data: a report from the Marfan Treatment Trialists’ Collaboration. 
Am Heart J 2015; 169: 605–12.
